PRO-101: A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants with ALS (clinicaltrials.gov) - Mar 4, 2025 - P1 | N=72 | Recruiting | Sponsor: ProJenX | N=32 ➔ 72 | Trial completion date: Jul 2022 ➔ Oct 2026 | Trial primary completion date: May 2022 ➔ Jun 2026
Enrollment change • Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders
|